Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Mechanisms of bone loss and gain in untreated and treated osteoporosis.

× No keyword cloud information.

56 in total

1. Cortical remodeling following suppression of endogenous estrogen with analogs of gonadotrophin releasing hormone.

Authors: K L Bell; N Loveridge; P C Lindsay; M Lunt; N Garrahan; J E Compston; J Reeve
Journal: J Bone Miner Res Date: 1997-08 Impact factor: 6.741

2. Fluoride: the verdict is in, but the controversy lingers.

Authors: M Kleerekoper
Journal: J Bone Miner Res Date: 1996-05 Impact factor: 6.741

3. Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells.

Authors: H Dobnig; R T Turner
Journal: Endocrinology Date: 1995-08 Impact factor: 4.736

4. Continuous parathyroid hormone and estrogen administration increases vertebral cancellous bone volume and cortical width in the estrogen-deficient rat.

Authors: H Zhou; V Shen; D W Dempster; R Lindsay
Journal: J Bone Miner Res Date: 2001-07 Impact factor: 6.741

5. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib.

Authors: T Mashiba; T Hirano; C H Turner; M R Forwood; C C Johnston; D B Burr
Journal: J Bone Miner Res Date: 2000-04 Impact factor: 6.741

6. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women.

Authors: G Y Boivin; P M Chavassieux; A C Santora; J Yates; P J Meunier
Journal: Bone Date: 2000-11 Impact factor: 4.398

7. Human parathyroid hormone-(1-34) increases bone mass in ovariectomized and orchidectomized rats.

Authors: J M Hock; I Gera; J Fonseca; L G Raisz
Journal: Endocrinology Date: 1988-06 Impact factor: 4.736

8. The effect on vertebral bone mass and strength of long term treatment with antiresorptive agents (estrogen and calcitonin), human parathyroid hormone-(1-38), and combination therapy, assessed in aged ovariectomized rats.

Authors: L Mosekilde; C C Danielsen; J Gasser
Journal: Endocrinology Date: 1994-05 Impact factor: 4.736

9. Bone histomorphometric changes after cyclic therapy with phosphate and etidronate disodium in women with postmenopausal osteoporosis.

Authors: S M Ott; G C Woodson; W E Huffer; P D Miller; N B Watts
Journal: J Clin Endocrinol Metab Date: 1994-04 Impact factor: 5.958

10. Marked decrease in trabecular bone quality after five years of sodium fluoride therapy--assessed by biomechanical testing of iliac crest bone biopsies in osteoporotic patients.

Authors: C H Søgaard; L Mosekilde; A Richards; L Mosekilde
Journal: Bone Date: 1994 Jul-Aug Impact factor: 4.398

2 in total

1. Aging alters bone-fat reciprocity by shifting in vivo mesenchymal precursor cell fate towards an adipogenic lineage.

Authors: Lakshman Singh; Tracy A Brennan; Elizabeth Russell; Jung-Hoon Kim; Qijun Chen; F Brad Johnson; Robert J Pignolo
Journal: Bone Date: 2016-01-19 Impact factor: 4.398

2. The effects of binge alcohol exposure on bone resorption and biomechanical and structural properties are offset by concurrent bisphosphonate treatment.

Authors: John J Callaci; Dainius Juknelis; Avinash Patwardhan; Mark Sartori; Nathan Frost; Frederick H Wezeman
Journal: Alcohol Clin Exp Res Date: 2004-01 Impact factor: 3.455

2 in total